187.75 -0.53 (-0.28%)
After hours: 4:53PM EDT
|Bid||187.30 x 200|
|Ask||188.19 x 100|
|Day's Range||187.06 - 192.01|
|52 Week Range||182.80 - 256.80|
|PE Ratio (TTM)||5.74|
|Earnings Date||Nov 1, 2017|
|Forward Dividend & Yield||2.80 (1.42%)|
|1y Target Est||250.72|
Another analyst is weighing in on the growing guesswork regarding the likelihood that Allergan (AGN) could be heading for a break up. Allergan is appealing the decision, though the outcome of such a move is far from certain. Meanwhile, several analysts warn that a cheaper-priced generic version of Restasis could hit the U.S. market next year, eroding sales of Allergan’s second-biggest selling drug and creating a $1.5 billion revenue hole.
Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.
San Diego-based Imprimis' therapy will cost 99 cents for a month's supply, with refills starting at $79 a month and the company will start selling prescriptions on Nov. 1, Imprimis' Chief Executive Mark Baum told Reuters. Allergan recently stirred controversy after striking a deal with the Native American Saint Regis Mohawk tribe that would shield certain patents on Restasis.
Is Allergan (AGN) worth the risk? That’s the question analysts and investors are tackling this week after the drug maker got rocked by a federal court ruling that invalidated some of the patents protecting ...
Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.
Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.
Allergan (AGN) fell to the bottom of the S&P 500 today as analysts predicted that the drug maker’s blockbuster eye drug Restasis could see a generic rival as soon as next year. Shares of Allergan fell more than 5.3% to close at $187.15 a share, on a day when the index edged 0.7% lower. On Monday, Allergan got rocked when a federal judge invalidated some of the patents protecting Restasis, opening the door for generic rivals that could push Allergan’s second-biggest selling drug off a cliff.
Keith Bliss of Cuttone and Company joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the current rally in stocks and the importance of tax cuts.